Immorta Bio's SenoVax Reduces Solid Tumors
Slice of Healthcare Team
12/09/2025
Key highlights
- Significant tumor shrinkage in murine models.
- Targeted immunotherapy against senescent cells.
- Submitted IND to the FDA for first-in-human trials.
Source: PR Newswire
Notable Quotes
“ These data provide compelling proof-of-concept that immunizing against senescent cells represents an entirely new therapeutic modality in oncology. ”
Dr. Thomas Ichim, President and Chief Scientific Officer at Immorta Bio
“ Converting the tumor microenvironment into a more inflamed, T-cell-friendly state by eliminating senescent cells could dramatically broaden the reach of checkpoint inhibitors and other immune therapies. ”
Dr. Gilberto Lopes, Chief of Thoracic Medical Oncology at Sylvester Comprehensive Cancer Center
“ This study provides foundational evidence for clinical development of senescent-cell–directed therapies in oncology, with potential future application to other aging-related biological processes. ”
Dr. Boris Reznik, Chairman and CEO at Immorta Bio
Why this matters
The results from Immorta Bio's study indicate a transformative approach to cancer treatment by harnessing the immune system to target senescent cells, opening avenues for therapies in previously resistant tumor types. This development is particularly significant for the healthcare sector.
Expert Insights
Share Your Expert Insights
Have relevant experience or professional perspective? Add your thoughtful insights to this article.
